Australia’s approval of MDMA and psilocybin for PTSD and depression is premature, say critics
British medical journal July 11, 2023 B. Nogrady 18 citations
The Australian Therapeutic Goods Administration (TGA) imposed specific conditions on the use of MDMA and psilocybin for therapeutic purposes: only psychiatrists who are trained and authorized to prescribe these substances may do so, each patient case must be approved by a human research ethics committee, and the treatments must be combined with psychotherapy. Additionally, a TGA officer and the ethics committee must confirm that a suitably robust treatment protocol has been developed.